 In addition, nilutamide, a closely related antiandrogen with the same mechanism of action as bicalutamide, has been evaluated in transgender women in at least five small clinical studies.It was given at a high dosage of 300 mg/day, the same dosage at which it has been used as a monotherapy in the treatment of prostate cancer.The corresponding monotherapy dosage of bicalutamide in the treatment of prostate cancer is 150 mg/day.